Dr. Rudolf Kwan has been appointed chief medical officer at Kinex Pharmaceuticals, and Dr. Wing-Kai Chan has been named head of clinical operations, Asia/Pacific. Dr. Kwan has more than 25 years of clinical drug development experience. Prior to joining the company, he served as head of clinical operations for U.S., Latin America and Asia-Pacific at Schering-Plough Research Institute, with responsibility for all clinical development globally. Dr. Kwan will be based in NJ.
Dr. Chan previously held roles including director, National Center of Excellence for Clinical Trial and Research at the National University Hospital, Taiwan, and medical director in Roche Asia/Pacific. Dr. Chan is a member of American Society of Clinical Oncology and has authored many publications in clinical oncology. Dr. Chan will be based in Taipei, Taiwan and Hong Kong.
Dr. Johnson Lau said, "We are thrilled to add Dr. Kwan and Dr. Chan to the executive team. These appointments are very consistent with the continued evolution of Kinex into a Global Drug Development Organization as we progress several drugs further in the clinic. In addition, their clinical drug development experience spans across multiple continents and ideally positions them to lead our clinical programs and strategies and also work collaboratively with the Kinex partnerships previously announced."